Snehal Gis: Gene Therapy Revolutionizing the Hemophilia Treatment Landscape
Snehal Gis, Senior Digital Analyst Manager and Senior Research Associate at Global Insight Services shared a post on LinkedIn:
”The Hemophilia Gene Therapy Market is entering a transformative phase, driven by the promise of long-term or potentially curative treatments for patients suffering from hemophilia, a rare genetic bleeding disorder.
Unlike traditional therapies that rely on frequent factor replacement infusions, gene therapy introduces functional copies of defective genes into a patient’s cells, enabling the body to produce clotting factors naturally.
This shift represents a paradigm change in treatment approaches, offering improved quality of life and reduced lifetime healthcare costs.
Click to Request a Sample of this Report for Additional Market Insights.”
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 03:53Nahrwan Masaoodi: Iron Deficiency Can Exist Without Anemia
-
Sep 29, 2026, 03:38Muhammad Yousaf: Iron Deficiency Beyond Diet
-
Sep 29, 2026, 03:21Parvez Ahmed Chowdhury: Synthesizing Aspirin in the Organic Chemistry Lab
-
Sep 29, 2026, 03:12Ahmed Hamandi: Building the Future of Hematopoietic Transplantation in Iraq
-
Sep 29, 2026, 03:09M V Chandrakanth: Aspirin in CRC – Old Drug, New Precision Oncology?
-
Sep 29, 2026, 03:07Caroline Pothet: Advancing Treatment Development in Sickle Cell Disease and Thalassaemia
-
Sep 29, 2026, 02:53Astha Jain: Thalassemia Care Through a Public Health Lens
-
Sep 29, 2026, 02:50Emma Groarke: Starting a New Career Path in Homeland
-
Sep 28, 2026, 19:14Aditya Sharma: An Outstanding Start to the Final Day of VSS 2026!